Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Myositis: early-phase trial registry

5 of 9 indexed Myositis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Myositis: 9 US clinical trials tracked, 5 recruiting.

Myositis is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 2 of these trials.

Enrollment posture brief

Registry condition myositis

OPEN 5 | RECR 56% | LATE 1 | EARLY 6 | RANK #1916 | SPON 2

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Myositis (this)56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Myositis

Myositis lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Myositis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Myositis is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Myositis research.

    argenx accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Myositis enrolment sits around 90 participants.

    Median target enrolment is 90 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Myositis research is mostly interventional.

    7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31

Open and recent trials

9 total, page 1 of 1

RECRUITING 700 participants

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

Myositis International Health & Research Collaborative Alliance Foundation

NCT07374107

RECRUITING 580 participants

Environmental Risk Factors for the Anti-synthetase Syndrome

National Institute of Environmental Health Sciences (NIEHS)

NCT01276470

RECRUITING Phase 3 318 participants

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Pfizer

NCT05895786

RECRUITING Phase 2 90 participants

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Artiva Biotherapeutics

NCT06991114

RECRUITING Phase 1 80 participants

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

CRISPR Therapeutics

NCT06925542

ACTIVE NOT RECRUITING Phase 2 265 participants

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

argenx

NCT05523167

ACTIVE NOT RECRUITING Phase 2 36 participants

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Janssen Research & Development

NCT05379634

ACTIVE NOT RECRUITING Phase 2 3 participants

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

argenx

NCT06284954

COMPLETED Phase 1 19 participants

Study of Pioglitazone in Sporadic Inclusion Body Myositis

Johns Hopkins University

NCT03440034

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Myositis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PBO Other
1 trials
EFG PH20 SC Biological
1 trials
Glucocorticoids Drug
1 trials
Allogeneic NK Cells Drug
1 trials
Placebo IV Other
1 trials
Empasiprubart IV Biological
1 trials
No intervention - qualitative and mixed methods investigations Other
1 trials
PF-06823859 Drug
1 trials

US sites by state

Facility locations filed on Myositis trials. A trial with sites in several states counts in each.

Florida 6 trials
California 6 trials
Arizona 4 trials
North Carolina 3 trials
Maryland 3 trials
Massachusetts 3 trials
Illinois 3 trials
Texas 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Myositis page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Myositis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • argenx sponsors the most Myositis trials on record, review their full trial history before evaluating a specific study. See argenx's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myositis condition card totals 9 registered trials; most-linked intervention PBO; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.